The emergence of tumor resistance to conventional microtubule-targeting drugs restricts their clinical use. Using a cell-based assay that recognizes microtubule polymerization status to screen for chemicals that interact with regulators of microtubule dynamics, we identified Pyr1, a cell permeable inhibitor of LIM kinase, which is the enzyme that phosphorylates and inactivates the actin-depolymerizing factor cofilin. Pyr1 reversibly stabilized microtubules, blocked actin microfilament dynamics, inhibited cell motility in vitro and showed anticancer properties in vivo, in the absence of major side effects. Pyr1 inhibition of LIM kinase caused a microtubulestabilizing effect, which was independent of any direct effects on the actin cytoskeleton. In addition, Pyr1 retained its activity in multidrug-resistant cancer cells that were resistant to conventional microtubuletargeting agents. Our findings suggest that LIM kinase functions as a signaling node that controls both actin and microtubule dynamics. LIM kinase may therefore represent a targetable enzyme for cancer treatment.
Introduction
Microtubules are filaments composed of a-tubulin and b-tubulin heterodimers. They are highly dynamic polymers, and their dynamics is tightly regulated by a balance between activities of microtubules-stabilizing and microtubule-destabilizing proteins (1) (2) (3) .
Moreover, the interaction of the microtubule growing tips with some proteins such as CLIP 170 results in microtubule stabilization (4, 5) . The binding of all of these proteins to tubulin is tightly regulated by phosphorylation/dephosphorylation processes (6, 7) or, directly, by tubulin modifications such as the tubulin tyrosination cycle (8, 9) . A detailed knowledge of the different players and how they interact both spatially and temporally to regulate microtubule functions is, however, still lacking.
Because of microtubules key role in mitosis, microtubuletargeting agents are powerful anticancer drugs. Tubulin is now considered as one of the most highly validated cancer target (10, 11) . These drugs have, however, some limitations due to side effects, principally myelosuppression and neurotoxicity. Moreover, many cancers are, or become, resistant to these drugs (12) . This is often the result of multidrug resistance caused by overexpression of ATP-binding cassette transporters (13) . Several strategies have been proposed for the development of more effective and less toxic anticancer drugs. One of them is to identify drugs targeting proteins that regulate microtubule functions and that would lead to mitotic arrest and/or apoptosis.
The aim of this study was to identify chemical compounds able to interact with regulators of microtubule dynamics. We therefore conducted a screening using a cell-based assay that probes the microtubule polymerization status (14) . We identified a compound (Pyr1) that slows down microtubule dynamics. Pyr1 is toxic for cancerous cell lines, including drugresistant cell lines. Pilot studies on mice with xenografted tumors indicate that Pyr1 prevented tumor growth and was well tolerated. Pyr1 also affected the actin cytoskeleton and inhibited cell motility. We have identified LIM kinases (LIMK) as the main targets of Pyr1. The activity of LIMK1/2 is regulated mainly by the Rho-dependent kinases ROCK1 (15) and ROCK2 (16) and the p21-activated kinases PAK1 (17) and PAK4 (18) and inactivated mainly by the slingshot phosphatases (19) . Phosphorylation and inhibition of the actin-depolymerizing protein cofilin by LIMKs is the last step of a cascade that regulates actin polymerization. Here, we show that Pyr1 inhibits cofilin phosphorylation. We established that the microtubule-stabilizing effect of Pyr1 results from its inhibitory effect on LIMKs and is independent of its effect on the actin cytoskeleton. Thus, LIMK inhibition by Pyr1 explains the observed phenotypes on both actin and tubulin.
Materials and Methods

Screen for chemical modulators of microtubule dynamics
The screen was conducted as described in the work of Vassal and colleagues (14) . For a summarized description, see the Supplementary Methods.
Chemical reagents, recombinant and purified proteins, plasmids, antibodies, and cell lines All reagents used are indicated in the Supplementary Methods.
Immunofluorescence microscopy
To visualize microtubules, cells were seeded either on glass coverslips or in microplates (ViewPlate-96, Perkin-Elmer Inc.). They were permeabilized in warm OPT buffer (80 mmol/L Pipes, 1 mol/L EGTA 1 mol/L MgCl 2 , 0.5% Triton X-100, and 10% glycerol, pH 6.8) and fixed for 6 minutes in À20 C methanol. To visualize F-actin, cells were washed in warm PBS and fixed with 4% paraformaldehyde in PBS at 37 C, followed by cell permeabilization with 0.1% Triton X-100 in PBS. After incubation with primary antibodies, cells were incubated with Cy3 (Jackson ImmunoResearch Laboratories) or Alexa 488 (Invitrogen) secondary antibodies. To visualize Factin, Alexa 488-phalloidin (Invitrogen) was included with the secondary antibody.
Images were captured either with a charge-coupled device camera (CoolSNAP ES; Roper Scientific) in a straight microscope (Nikon Eclipse 90i) controlled by Nikon software (Universal Imaging Corp.) using a Â40, Â60, or Â100 Plan-Neofluar oil objectives, with an IN Cell Analyzer 1000 automated microscope (GE-Healthcare) using a Â40 objective, controlled by IN Cell software allowing automated cell imaging or with an Orca R2 N/B camera (Hamamatsu) in a straight microscope (Zeiss AxioImager Z1) controlled by Axiovision software (Carl Zeiss) using a Â63 oil objective. When necessary, cells were observed with a confocal microscope (Leica).
Immunofluorescence analysis of growing microtubules þ ends HeLa cells were incubated for 2 hours with the tested compound, fixed for 6 minutes in À20 C methanol, and processed for immunofluorescence using anti-EB1-specific antibody.
Tubulin polymerization assay
Microtubule polymerization assay was adapted from the work of Bonne and colleagues (20) . Briefly, microtubule assembly was carried out in a half-area, 96-well black plate (Greiner, #675090) using a microplate reader FLUOstar OPTIMA (BMG Labtechnologies). Wells were charged with either microtubule proteins or pure tubulin (final concentration of 25 and 30 mmol/L, respectively) in MEM buffer with 10 mmol/L 4 0 ,6-diamidino-2-phenylindole (DAPI) and variable concentrations of compounds. Following 10-minute incubation, assembly was started by injection of GTP and MgCl 2 to a final concentration of 1 and 5 mmol/L, respectively, in 100 mL. The excitation and emission wavelengths were set at 360 and 450 nm, respectively, and the fluorescence of microtubule-bound DAPI was monitored as a function of time at 37 C. Fluorescence signal at time 0 was subtracted from each of the subsequent fluorescence readings. Each compound was assayed in triplicate.
Actin-pyrene polymerization assay
Mg-ATP-monomeric actin (2 mmol/L, 10% pyrene labeled) in MME buffer containing 0.2 mmol/L ATP was polymerized at room temperature after addition of one-tenth volume of Â10 buffer (500 mmol/L KCl, 20 mmol/ MgCl 2 , 2 mmol/L EGTA, 100 mmol/L imidazole, pH 7.5). Experiments were carried out in the presence or absence of different compounds, as indicated in the figure legend. The polymerization was followed by changes in pyrene fluorescence using a Xenius SAFAS fluorimeter (Safas SA).
Tumor xenograft experiments
Twelve B6D2F1 female mice were injected subcutaneously in the right flank with 2 Â 10 6 L1210 cells. Mice were then randomly separated into 2 groups of 6 mice each. In one group, Pyr1 (10 mg/kg/d in PEG400) was injected intraperitoneally, on the left flank, daily for 10 days. In the other group, PEG400 alone was injected, daily for 10 days. Each day, the mice were observed for survival. They were weighted twice a week. The experiment was stopped 20 days after the last vehicle-treated mice death. The ethics committee of Lyon University (Lyon, France) validated this experimental protocol.
All the other experimental procedures are described in the Supplementary Methods.
Results
Hits selection process
The screening assay is based on the properties of the tubulin enzymes involved in the tubulin tyrosination cycle, tubulin tyrosine ligase, and tubulin carboxypeptidase. Because of their substrate properties, dynamic microtubules are composed of tyrosinated tubulin (Tyr-tubulin), whereas stabilized microtubules are composed of detyrosinated tubulin (Detyr-tubulin; ref. 21) . Thus depolymerization or stabilization of the microtubule network can be distinguished by double immunofluorescence using specific Tyr-and Detyrtubulin antibodies (14) . We selected 16 compounds that enhance the Detyr-tubulin signal by 20%. After checking the compounds structure, only 5 chemically nonreactive compounds that generate stable Detyr-microtubules in cells were selected for further characterization (Supplementary Table S1 ).
It is well established that sodium azide can stabilize microtubules, thus generating Detyr-tubulin (22) . To eliminate compounds acting via similar mechanisms, we analyzed compounds effects on mitochondria and discarded compounds targeting mitochondria as did sodium azide (Supplementary Table S1 ). We also eliminated compounds with no analogues, leaving one remaining compound, 9-benzoyloxy-5,11-dimethyl-2H,6H-pyrido [4,3-b] carbazol-1-one, (Pyr1; Fig. 1A ). Incubation of HeLa cells with 25 mmol/L of Pyr1 resulted in Detyr-microtubules generation (Fig. 1B) .
Pyr1 suppresses microtubule dynamic instability without directly targeting tubulin
To check whether the enrichment of Detyr-microtubules results from an effect on the tubulin tyrosination enzymes or from an effect on microtubules dynamics, we first studied the resistance of the microtubule network to nocodazole-induced depolymerization. Nocodazole binds free tubulin and prevents its incorporation into microtubules, inducing microtubule depolymerization. Microtubules with slow dynamics have reduced exchanges with the free tubulin pool and are thus less sensitive to nocodazole-induced depolymerization (23) . We found that a pretreatment of cells with Pyr1 protects the microtubule network from nocodazole-induced depolymerization ( Fig. 2A) . We next examined the distribution of the plusend tracking protein (þTIP) EB1 (end binding protein 1) that specifically probes growing microtubule plus ends. Cells treated with dimethyl sulfoxide (DMSO), 5 mmol/L paclitaxel, or 10 and 25 mmol/L Pyr1 were stained with an anti-EB1-specific antibody (Fig. 2B ). We observed a decrease of the number of EB1 comets per cell in paclitaxel-treated cells (92% reduction of the number of EB1 comets) as well as in cells treated with Pyr1 (84% reduction of the number of EB1 comets for 25 mmol/L Pyr1), together with a size reduction of remaining EB1 comets (45% and 27% reduction of the comets surface for 5 mmol/L paclitaxel and 25 mmol/L Pyr1, respectively), suggesting a strong reduction of microtubule growth dynamics ( Supplementary Fig. S1 ).
We then analyzed the effect of Pyr1 on microtubule dynamic instability parameters, using time lapse fluorescence microscopy on GFP-EB3-transfected cells (ref. 24 ; Supplementary Movie S1). As expected, Pyr1 suppressed the microtubule growth rate, strongly reduced the microtubule growth length as indicated by the dose-dependent increase of the distancebased catastrophe frequency, and increased time spent in pause. Such effects have been previously described for microtubule-stabilizing agents (ref. 25 ; Supplementary Table S2) . Taken together, these experiments clearly show that Pyr1 suppresses microtubule dynamics instability.
Close analysis of the morphology of the mitotic spindles revealed that the spindles of cells treated with the compound were abnormal, with disorganized asters. We found that 84.2% of the mitotic spindles were normal in DMSO-treated cells and 12.8% abnormal, whereas 9.7% of the mitotic spindles were normal in Pyr1-treated cells and 82.9% were abnormal. These defects were clearly different from the multiple asters observed in cells treated with paclitaxel. Spindles depolymerize in nocodazole-treated cells (Fig. 2C) .
As agents interfering with microtubule dynamics lead to a G 2 -M cell-cycle arrest, we analyzed Pyr1 effect on the cell cycle, by flow cytometry. Although Pyr1 effect was not as strong as that of nocodazole or paclitaxel, we found that it induced a cell-cycle arrest at the S-to G 2 -M phases (Fig. 2D) .
To test whether Pyr1 directly interacts with tubulin, we assayed it in an in vitro tubulin assembly. Paclitaxel is a wellcharacterized microtubule-stabilizing agent that can induce in vitro tubulin assembly at low tubulin concentrations that would not induce spontaneous tubulin assembly. We found that Pyr1 could not induce in vitro tubulin assembly, neither when assayed on tubulin in the presence of associated protein (microtubule proteins, Fig. 2E ) nor on pure tubulin (Fig. 2F ). This experiment strongly suggests that Pyr1 does not interact directly with tubulin.
Pyr1 overcomes drug-resistant cell phenotype Because Pyr1 was able to stabilize microtubules, with a mechanism of action different to that of taxanes, we tested whether it could be of therapeutic interest. We first examined its toxicity on several cancerous cell lines, including drugresistant cell lines overexpressing the glycoprotein P or transporters such as ABCG2 and MRP1 that renders cells insensitive to current chemotherapies.
Pyr1 reduced the viability of these cell lines in a dosedependent manner, with a GI 50 (50% of growth inhibition) in the micromolar range (Table 1) . The cell-cycle parameters were analyzed by flow cytometry. Histograms represent the percentage of the total cell population in each cell-cycle phase: sub-G 1 (yellow), G 1 (blue), S (green), G 2 -M (red), >4N (purple). E and F, microtubule proteins (E) and pure in vitro tubulin (F) polymerization assay. Tubulin (0.5 mg/mL for microtubule proteins and 1 mg/mL for pure tubulin) was allowed to polymerize at 37 C in the presence of 1 mmol/L paclitaxel (red), 25 mmol/L Pyr1 (green), or equivalent amount of DMSO (0.25%, orange). Results are presented as mean AE SEM of 3 independent experiments. Bars, 10 mm. A.U., arbitrary units.
Interestingly, Pyr1 toxicity is the same for the drug-sensitive human cell lines and for their multidrug-resistant counterparts, indicating that it is not substrate of the glycoprotein P or of ABCG2 and MRP1 transporters.
Pyr1 is well tolerated in mice and shows anticancer activity
The core structure of Pyr1 is similar to that of ellipticine, an alkaloid with proven antineoplastic activity, through DNA intercalation and inhibition of topoisomerase II. The ellipticine derivative N2-methyl-9-hydroxyellipticium has been used in the treatment of breast cancer, but it has been retrieved because of its toxicity. Previous studies have shown that Pyr1 is a weak DNA intercalator and has no effect on topoisomerase II (26) .
To determine whether Pyr1 could serve as chemotherapeutic agent, we examined its toxicity in mice. Mice received daily intraperitoneal injections of Pyr1 (from 15 to 60 mg/kg), during 7 days. Transient signs of discomfort related to administration of the vehicle were observed in all animals (Supplementary Table S3 ). The weights of Pyr1-treated animals and vehicletreated animals were not significantly different (Supplementary Table S4 ). Hematologic parameters were normal after Pyr1 treatment. The only small changes observed for the highest doses were not considered as having significant toxicity (Supplementary Table S5 ). After treatment period, a full postmortem examination was conducted. Yellow foci on the liver for mice that received high dose of Pyr1 were observed, which correlated with acute to subacute peritoneal inflammation seen in the hepatic capsule (data not shown) but without signs of severe hepatic damage. Thus, under these experimental conditions, no severe adverse effects related to Pyr1 administration were observed up to the dose of 30 mg/kg/d, indicating that Pyr1 is well tolerated.
We then conducted a pilot study using an in vivo model of leukemia L1210-bearing mice of the B6D2F1strain. The injected dose of Pyr1 was chosen to be 3 times lower than the dose (30 mg/kg/d) for which the first adverse signs were detected. Vehicle-treated mice were all dead at day 70, whereas all the Pyr1-treated mice survived (Fig. 3) and were still alive 20 days later, when the experiment was stopped. Thus, Pyr1 induced a complete survival gain (P < 0.002) with no apparent toxicity (no loss of weight, data not shown).
These experiments indicate that Pyr1 has a good therapeutic efficacy and is well tolerated.
Pyr1 affects the organization of F-actin but does not directly target it
We then tried to identify Pyr1 cellular targets. As the microtubule and actin microfilament networks are highly interconnected (27) , we investigated the effect of Pyr1 on the actin cytoskeleton. Cells treated with Pyr1 were stained for filamentous actin (F-actin) using fluorescein-phalloidin. Pyr1 affected the organization of the actin microfilaments, which was not observed when cells were exposed to paclitaxel (Fig. 4A) . Because of the central role of actin dynamics in cell motility, we examined the effect of Pyr1 on MCF10A cells motility, using time lapse video microscopy. We found that Pyr1 rapidly and completely blocked cell motility, even at the lowest concentration assayed (10 mmol/L; Fig. 4B ).
Pyr1 was not able to directly affect actin assembly in vitro and could not modify actin assembly kinetics, contrary to phalloidin that can stabilize F-actin in vitro and to latrunculin B that inhibits actin assembly (Fig. 4C) . These results indicate that Pyr1 does not directly interact with actin.
We have also tested the possibility that the effect of Pyr1 on F-actin influences microtubule dynamics, which could indirectly result in the stabilization of microtubules. We thus pretreated cells with cytochalasin D, which depolymerizes F-actin (28) , and examined Pyr1 effect on microtubule dynamics (Supplementary Fig. S2 ). We observed that even when the microfilaments are completely depolymerized, Pyr1 still induces the formation of Detyr-microtubules, indicating that the microtubule network is stabilized. This result strongly suggests that Pyr1-induced microtubule stabilization is independent of the inhibitor effect on the actin network.
Taken together, these findings indicate that Pyr1 targets regulators of actin as well as tubulin.
Pyr1 selectively inhibits LIM kinases activity
Previous screening identified a class of Pyr1 structurally related compounds that often targets protein kinases (26, 29) . We therefore tested the ability of Pyr1 to inhibit the activity of a panel of 66 protein kinases known to be involved in the regulation of the cytoskeleton. Pyr1 inhibited only the activities of a member of NIMA-related kinase family (NEK11), mixed lineage kinase 1 (MLK1), and LIM kinase 1 (LIMK1; Fig. 5A and Supplementary Table S6 ). The highest inhibition was observed for LIMK1, which showed only 4% residual in vitro kinase activity. A well-established substrate of LIMK1 is cofilin, a protein that regulates actin dynamics. Using cofilin as substrate, we found that Pyr1 inhibited the activity of recombinant LIMK1 and LIMK2 (Fig. 5B C) in vitro with an IC 50 of 50 and 75 nmol/L, respectively (Supplementary Fig. S3a ). The inhibitor behaved as an ATP competitor (Supplementary Fig. S3b) .
As selectivity is a major issue for ATP-competitive kinase inhibitors, we extended the evaluation of the compound on the activity of 45 additional different kinases, using a thermal stability shift assay (30) . We did not find significant interaction of the identified inhibitor with any of the screened kinases except LIMK1, which showed a T m shift of 8. 16 C, consisted with the high potency of this inhibitor (Supplementary  Table S7 ). Another substrate of LIMK1 is p25 (31) . We investigated the ability of Pyr1 to inhibit the in vitro phosphorylation of bacterially expressed and purified human GST-p25 by recombinant LIMK1. Although the phosphorylation of GST-p25 was not efficient in control conditions, we found that Pyr1 inhibits it (Fig. 5D) .
To ascertain that Pyr1 can also inhibit LIMK activity in cells, we examined the level of phospho-cofilin (p-cofilin) in cells treated for 2 hours with different concentrations of Pyr1. The level of p-cofilin was greatly reduced with increasing amounts of Pyr1, whereas the protein levels of cofilin were not affected. A complete inhibition of cofilin phosphorylation was observed after incubation of cells with 25 mmol/L of Pyr1 (Fig. 5E ). This concentration was chosen to determine the time course of Pyr1 effect in cells. Complete inhibition of cofilin phosphorylation was observed 20 minutes after addition of Pyr1 (Supplementary Fig. S3c) .
We also investigated whether the inhibition of LIMK1 activity by Pyr1 was reversible in vitro and in cells. To achieve this, the kinase activity of a LIMK1-Pyr1 mix was assayed before and after size exclusion chromatography, allowing the potential separation of the kinase from unbound inhibitor. After gel filtration, a significant increase in LIMK activity was observed ( Supplementary Fig. S3d ). Western blot analysis of protein lysates prepared from cells first treated with Pyr1 and then re-incubated in fresh medium without Pyr1 showed that cofilin phosphorylation was again detectable 30 minutes after Pyr1 washout and reached basal levels after 2 hours (Supplementary Fig. S3e) . These results clearly show that Pyr1 binding to LIMK is reversible.
Similarly, the suppression of microtubule dynamic instability by Pyr1 observed in HeLa cells was also found reversible (Supplementary Table S8) .
We also checked whether Pyr1 inhibits NEK11 and MLK1 activities. In vitro, Pyr1 has weak activity on both NEK11 and MLK1 ( Supplementary Fig. S4a and S4b). Pyr1 effect was also checked in cells. NEK11 is known to destabilize Cdc25A (32) and a downstream target of MLK1 is Jun kinase. Looking on Cdc25 expression and on the phosphorylation status of Jun kinase, respectively, we found that Pyr1 has no effect on the activity of neither NEK11 nor MLK1 ( Supplementary Fig. S4c and S4d).
LIMK inhibition causes microtubule stabilization
The identification of LIMK1/2 as targets of Pyr1 strongly suggested that the inhibition of cofilin phosphorylation is the mechanism that underlies the actin network reorganization and the loss of cell motility of cells treated with Pyr1. The link between LIMK inhibition and the observed microtubule stabilization is, however, less obvious. To investigate this issue, we compared the potency of several Pyr1 structural analogues to inhibit LIMK1 activity in vitro (Supplementary Table S9) , to modify actin microfilaments dynamics, as assessed by the resistance of Pyr1-induced actin structures to latrunculin depolymerization, to induce the generation of Detyr-microtubules ( Supplementary Fig. S5a ), and to inhibit cofilin phosphorylation in cells ( Supplementary Fig. S5b ). We found a good correlation between the levels of LIMK1 inhibition by the tested compounds and the stabilization of both the actin structures and the microtubules. These experiments also allowed the determination of Pyr1 structure-activity relationships (Supplementary Table S9 ).
In another experiment, we tested whether (N-[5-[2,6-dichloro-phenyl]-5-difluoromethyl-2H-pyrazol-3-yl]thiazol-2-yl)-isobutyramide, a recently described LIMK inhibitor (33, 34) , also called LIMKi (Fig. 6A) , was able to stabilize microtubules. We showed that LIMKi was indeed able to increase the Detyr-microtubules cell content (Fig. 6B ) and to stabilize them to a nocodazole-induced depolymerization (data not shown). These results indicate that an LIMK inhibitor structurally different from Pyr1 is also able to induce a stabilization of the microtubule network. We then tested whether the overexpression of LIMK1 could counteract the microtubule-stabilizing effect of Pyr1. Cells overexpressing LIMK1 (Fig. 6C) were treated with increasing concentrations of Pyr1 and microtubule stability was then probed with nocodazole, as described above. We found that at all the concentrations assayed, the microtubule network of the LIMK1-expressing cells treated with Pyr1 was less stabilized, as compared with control cells (Fig. 6D) .
Finally, we analyzed the effect of LIMK invalidation on microtubule stabilization, as assessed by the generation of Detyr-microtubules. We invalidated LIMK1 and LIMK2 into MCF7 cells and found that LIMK invalidation not only decreases cofilin phosphorylation but also increases Detyrtubulin content (Supplementary Fig. S6 ). We found that LIMK expression, especially that of LIMK2, was more difficult to silence into HeLa cells. We succeeded, however, using short hairpin RNA lentivirus, to diminish LIMK1 expression in such cells. In these conditions, we found a large amount of cells with Detyr-microtubules, indicating that microtubules are stabilized ( Supplementary Fig. S6 ).
Taken together, our results show that specific inhibition of LIMK activity by the small-molecule inhibitor Pyr1 is responsible of its effects on the cytoskeletal proteins tubulin and actin.
Discussion
Our strategy based on a screening of a chemical library led to the discovery of a cell-permeable inhibitor of LIMK1/2, enzymes known to phosphorylate and inactivate cofilin, an actin-depolymerizing factor. As the readout of the assay used for the library screening was the immunofluorescence detection of a tubulin modification indicative of the cellular microtubule stability status, it was somewhat surprising that this approach led to the identification of an inhibitor of a known actin regulator. However, such a whole-cell-based assay probes for inhibitors of entire pathways, allowing the cell biology to dictate the best targets (35) . Using cytochalasin D, an actin-depolymerizing agent, we showed that the effect of Pyr1 on microtubules was independent of its induced actin cytoskeleton reorganization. Thus, this screening approach allowed the selection of a chemical compound able to target LIMKs, a shared signaling regulation node of the actin and the microtubule cytoskeletons.
Because of the ability of Pyr1 to suppress microtubules dynamic instability, we tested whether it has antimitotic and cytotoxic properties on cancer cell lines. We found that this was the case. Moreover, Pyr1 had the same toxicity for the drug-sensitive human cell lines and for their multidrug-resistant counterparts. This suggests that Pyr1 may be used as an alternative or in addition to standard chemotherapy, in drugresistant tumors. Our pilot study conducted on tumors xenografts in mice indicated that Pyr1 was indeed able to prevent tumor growth at doses that are well tolerated by the animals.
Moreover, because it is active at doses much lower than the doses where the first signs of toxicity appear, Pyr1 has a convenient therapeutic window.
Although we found a close correlation between LIMK inhibition, actin disorganization, and microtubule stability, the mechanism by which Pyr1 induces microtubule stabilization is not completely understood. It was shown that phosphorylation of p25 by LIMK1 inhibits its ability to polymerize microtubules, resulting in reduced levels of stable microtubules (31) . Therefore, a Pyr1-induced dephosphorylation of p25 could be responsible of the observed stabilization of microtubules. We cannot, however, rule out the possibility that Pyr1-induced microtubule stabilization results from an effect of Pyr1 on other targets.
The mitotic spindles of cells treated with Pyr1 show a disorganization of astral microtubules. This phenotype is similar to that obtained by Kaji and colleagues after LIMK1 knockdown (36) , further supporting our conclusion that the LIMKs are the main cellular targets of Pyr1.
Pyr1 induced rapid and almost complete cofilin dephosphorylation in vitro and in cells. This indicates that the basal activity of cofilin phosphatases (slingshot and chronophin) must be high in the cells tested and that Pyr1 may also target closely related cofilin kinases, that is, TESK.
Pyr1 acts as an ATP-competitive inhibitor of LIMK. A major concern in the use of kinase inhibitors that are ATP antagonist is their target specificity, as the ATP-binding motif is present in all kinases as well as in other proteins. We therefore tested the ability of Pyr1 to inhibit the in vitro activity of 110 protein kinases, and although it is possible that Pyr1 targets other kinases such as TESK, than the ones already assayed, it shows, however, a high selectivity. The kinases assayed include some vital kinases such as the insulin receptor kinase. The absence of Pyr1 effect on these kinases could contribute to the observed limited animal toxicity of the compound.
It is anticipated that inhibition of cofilin phosphorylation that results in activation of cofilin would lead to actin severing and depolymerization of actin filaments. After 2 hours of treatment with Pyr1, we observed a complete disorganization of the actin microfilament network with decreased level of Factin. This phenotype was not previously observed when LIMK1 and LIMK2 were knocked down by specific siRNA (33) . A possible explanation of this disparity is that there are major differences between the mechanism of action of siRNA and pharmacologic inhibitors. Indeed, in addition to differences in kinetics, siRNA experiments reduce protein levels, whereas a small molecule only inhibits protein enzymatic activity. Moreover, LIMKs contain protein-protein interaction domains. They, thus, may have a variety of yet uncharacterized functions, in addition to their enzymatic activity. These other functions might be involved in the observed reorganization of the actin network.
One major advantage of small molecules, particularly when their effect is reversible, as is the case for Pyr1, is that they allow high temporal and spatial control. Their effects can be observed in real time by live cell imaging. To date only 2 cell-permeable inhibitors of LIMK have been described with limited experimental data about their specificity (33, 34, 37, 38) . Moreover,
